| 李杳瑶,刘 华,孙铜林,伍 静,孟小莎,伍梦思,苏联军.鳖甲煎丸联合阿帕替尼对中晚期肝癌TACE术后患者Th17/Treg平衡、凋亡分子和血管生成因子的影响[J].,2024,(7):1291-1295 |
| 鳖甲煎丸联合阿帕替尼对中晚期肝癌TACE术后患者Th17/Treg平衡、凋亡分子和血管生成因子的影响 |
| Effect of Biejiajian Pills Combined with Apatinib on Th17/Treg Balance, Apoptotic Molecules and Angiogenesis Factors in Patients with Middle and Late Liver Cancer after TACE |
| 投稿时间：2023-09-03 修订日期：2023-09-26 |
| DOI：10.13241/j.cnki.pmb.2024.07.017 |
| 中文关键词: 鳖甲煎丸 阿帕替尼 中晚期肝癌 肝动脉化疗栓塞术 Th17/Treg平衡 凋亡分子 血管生成因子 |
| 英文关键词: Biejiajian pills Apatinib Middle and late liver cancer Transcatheter arterial chemoembolization Th17/Treg balance Apoptotic molecules Angiogenesis factors |
| 基金项目:湖南省自然科学基金项目（2021JJ30523） |
|
| 摘要点击次数: 88 |
| 全文下载次数: 67 |
| 中文摘要: |
| 摘要 目的：观察鳖甲煎丸联合阿帕替尼对中晚期肝癌肝动脉化疗栓塞术（TACE）术后患者辅助性T 细胞17（Th17）/调节性T细胞（Treg）平衡、凋亡分子和血管生成因子的影响。方法：选取2021年1月至2022年12月湖南中医药大学第一附属医院收治的中晚期肝癌患者118例，患者均接受TACE并根据随机数字表法将患者分为对照组（59例，阿帕替尼治疗）和研究组（59例，鳖甲煎丸联合阿帕替尼治疗）。对比两组疗效、血清肿瘤标志物[甲胎蛋白（AFP）、癌胚抗原（CEA）、甲胎蛋白异质体3(AFP-L3)]、外周血Th17/Treg平衡[Th17细胞比例、Treg细胞比例、Th17/Treg比值]、凋亡分子[B淋巴细胞瘤-2相关X蛋白（Bax）、半胱氨酸天冬氨酸蛋白酶-4（Caspase-4）、半胱氨酸天冬氨酸蛋白酶-10（Caspase10）、B淋巴细胞瘤-2基因（Bcl-2）]和血管生成因子[血管生成素-2 （Ang-2）、血管内皮生长因子（VEGF）]。结果：研究组的临床总有效率高于对照组（P<0.05）。与对照组相比，研究组治疗后AFP、CEA、AFP-L3、Th17细胞比例、Th17/Treg比值、Bcl-2、Ang-2、VEGF更低，Treg细胞比例、Bax、Caspase-4、Caspase10更高（P<0.05）。两组不良反应发生率组间对比未见差异（P>0.05）。结论：鳖甲煎丸联合阿帕替尼治疗中晚期肝癌TACE术后患者，可有效阻止疾病进展，降低血清肿瘤标志物水平，可能与调节Th17/Treg平衡、凋亡分子和血管生成因子水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effect of biejiajian pills combined with apatinib on helper T cell 17 (Th17)/regulatory T cell (Treg) balance, apoptotic molecules and angiogenesis factors in patients with middle and late liver cancer after transcatheter arterial chemoembolization (TACE). Methods: 118 patients with middle and late liver cancer admitted to The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine from January 2021 to December 2022 were selected, patients received TACE and were divided into control group(59cases, received apatinib) and study group(59cases, biejiajian pills combined with apatinib)according to the random number table method. The efficacy, serum tumor markers [alpha-fetoprotein(AFP), carcinoembryonic antigen(CEA), alpha-fetoprotein-L3(AFP-L3)], peripheral blood Th17/Treg balance [Th17 cell ratio, Treg cell ratio, Th17/Treg ratio], apoptotic molecules [B-cell lymphoma-2 associated X protein(Bax), cysteine aspartic protease-4(Caspase-4), cysteine aspartic protease-10 (Caspase10), B-cell lymphoma-2 gene (Bcl-2)] and angiogenesis factors [angiopoietin-2 (Ang-2), vascular endothelial growth factor (VEGF)] were compared between two groups. Results: The total clinical effective rate in study group was higher than that in control group (P<0.05). Compared with the control group, the levels of AFP, CEA, AFP-L3, Th17 cell ratio, Th17/Treg ratio, Bcl-2, Ang-2 and VEGF were lower in the study group , and Treg cell ratio, Bax, Caspase-4, and Caspase-10 were higher after treatment(P<0.05). There was no difference in the incidence of adverse reactions between two groups(P>0.05). Conclusion: Biejiajian pills combined with apatinib in the treatment of patients with middle and late liver cancer after TACE, which can effectively prevent the progression of the disease, reduce the level of serum tumor markers, and may be relate to the regulation of Th17/Treg balance, apoptotic molecules and angiogenesis factors. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
